Sermorelin was originally FDA-approved for diagnosing GH deficiency in children, not for treating it in adults. The adult off-label use — restoring GH axis function in age-related decline — is what telehealth providers prescribe today. The original indication was pediatric GHD diagnosis at a single intravenous dose of 1 mcg/kg.
Sermorelin is used to treat age-related growth hormone decline in adults. The prescribing indication is documented low or low-normal IGF-1 on a baseline lab draw, accompanied by symptoms consistent with GH axis insufficiency: reduced lean mass, increased visceral fat, disrupted slow-wave sleep, low energy, and slow recovery from exercise. It is not FDA-approved for any current indication and is dispensed only as compounded medication.
- Primary use: age-related GH decline in adults, confirmed by low or low-normal baseline IGF-1
- It is prescribed off-label — the original FDA-approved indication (pediatric GHD diagnosis) was withdrawn in 2008
- A baseline IGF-1 draw is required before any legitimate prescriber will write a prescription
- Sermorelin is not used when pituitary function is insufficient to respond to GHRH stimulation
- It is not a weight loss drug, not a testosterone replacement, and not an anti-aging supplement
Primary Indication: Age-Related GH Decline
Growth hormone secretion declines steadily after age 30 [1], falling by roughly 14 percent per decade. By age 50, many adults have GH output at 50 to 60 percent of their peak. This age-related decline — sometimes called somatopause — is not a disease in the pathologic sense but produces measurable changes in body composition, sleep architecture, and metabolic function that respond to GH axis restoration. Sermorelin addresses this decline by stimulating the pituitary to increase its own GH output.
Every legitimate sermorelin program requires a baseline IGF-1 blood draw before the first prescription. IGF-1 is the downstream marker for GH axis activity. Without a baseline, there is no clinical rationale for treatment and no way to assess dose response at 90 days.
Symptoms That Indicate a Clinical Need
Sermorelin is appropriate when age-related GH decline is confirmed by labs and accompanied by symptoms. Low IGF-1 alone, without symptoms, does not automatically warrant treatment. The clinical picture matters.
- Reduced lean muscle mass despite consistent training and adequate protein
- Increased visceral and abdominal fat disproportionate to overall caloric intake
- Disrupted or non-restorative sleep — specifically reduced slow-wave sleep depth
- Low daytime energy, afternoon fatigue, and reduced exercise recovery
- Reduced collagen, skin elasticity, or joint mobility as secondary concerns
These symptoms are non-specific — they overlap with thyroid dysfunction, low testosterone, sleep apnea, and other conditions. A prescriber who moves from symptom report to prescription without confirming IGF-1 and ruling out competing diagnoses is not following a sound clinical standard. The baseline IGF-1 draw is what separates a medically justified prescription from an unsupported one.
What Sermorelin Is Not Used For
Sermorelin is not appropriate for several adjacent use cases that patients sometimes expect it to cover.
| Expected use | Why sermorelin does not fit |
|---|---|
| Rapid weight loss | Sermorelin restores GH axis function; it does not cause direct fat loss. Body composition changes develop over 3 to 6 months with concurrent lifestyle factors. |
| Testosterone replacement | Sermorelin works on the GH axis, not the HPG axis. It may improve testosterone indirectly in men with GH-related testosterone suppression, but it is not a TRT substitute. |
| Athletic performance enhancement | Sermorelin is not approved or appropriate for performance enhancement in healthy athletes with normal GH axis function. |
| Severe GH deficiency from pituitary disease | Sermorelin requires a functional pituitary. Adults with pituitary tumors, radiation damage, or confirmed pituitary insufficiency need exogenous HGH, not a GHRH analog. |
| Children | The current compounded form is not approved or used for pediatric GHD. |
Why Sermorelin Is Prescribed Off-Label
The original FDA-approved sermorelin product (Geref by Serono) was approved for two indications: diagnosing GH deficiency in children, and treating idiopathic GH deficiency in children. Both were pediatric indications. Geref was voluntarily withdrawn from the US market in 2008 for commercial reasons, not safety. Adult off-label use — treating age-related GH decline — is what telehealth providers prescribe today under a valid physician prescription for compounded sermorelin.
Off-label prescribing is legal and common in US medical practice. A physician may prescribe any legally available compound for a use not specified in the original labeling when clinical judgment supports it. The evidence base for sermorelin in adult GH decline is peer-reviewed: Walker (2006) [2] reviewed outcomes data and Sigalos and Pastuszak (2018) [3] reviewed safety and efficacy across the GH secretagogue class.
Who Is Not a Candidate
- Adults with active or history of malignancy — GH stimulation is contraindicated
- Adults with confirmed pituitary insufficiency — sermorelin requires a functional pituitary to work
- Adults with uncontrolled diabetes — GH elevation worsens insulin resistance
- Adults with severe sleep apnea — GH elevation can worsen the condition
- Adults whose IGF-1 is within normal range for their age — no clinical basis for treatment
Bottom Line
Sermorelin is used for one primary purpose: restoring GH axis function in adults with age-related GH decline confirmed by a low or low-normal baseline IGF-1. It is not a weight loss drug, not a testosterone replacement, and not appropriate when the pituitary cannot respond to GHRH stimulation. A provider who prescribes sermorelin without a baseline IGF-1 draw is not following a defensible clinical standard.
Frequently Asked Questions
Do I need a prescription for sermorelin?
Yes. Compounded sermorelin is a prescription medication. Any platform offering sermorelin without a physician consultation and valid prescription is operating outside federal law. This includes online vendors selling research-grade peptides, which are not intended or tested for human injection. Telehealth providers that follow a sound clinical standard require a consultation, a baseline IGF-1 draw, and a physician-issued prescription before dispensing.
Can sermorelin help with weight loss?
Sermorelin is not a weight loss drug. It restores GH axis function, which improves lipolysis and lean mass preservation over a 3 to 6 month protocol. Patients who are in a caloric deficit and exercising consistently will see the greatest body composition benefit from that effect. Patients who expect direct, rapid fat loss similar to GLP-1 agonists (semaglutide, tirzepatide) will be disappointed. The mechanism and timeline are fundamentally different.
What lab results qualify someone for sermorelin?
A low or low-normal IGF-1 is the primary qualifying marker. Normal ranges are age-adjusted — a result at the bottom of the reference range for a 50-year-old is not the same clinical picture as a result at the bottom of the range for a 30-year-old. A prescriber using sermorelin appropriately will review the IGF-1 result in context of symptoms and age, not apply a single cutoff number across all adults.
Can sermorelin be used alongside testosterone replacement therapy?
Yes, and combination protocols are common in men's health telehealth. Testosterone and GH work synergistically: testosterone amplifies the GH pulse amplitude and GH supports lean mass preservation and fat metabolism. Some providers offer combined TRT and sermorelin protocols. The GH and HPG axes are separate systems; sermorelin does not replace or interfere with testosterone replacement.
Is sermorelin safe long-term?
The safety profile at standard therapeutic doses is well-documented. Walker (2006) reviewed outcomes data from adult sermorelin use and noted tolerability consistent with the original pediatric Geref clinical data. The somatostatin feedback loop limits GH output, which is the primary safety advantage over exogenous HGH. The most common adverse events are injection-site reactions. Long-term protocols beyond 12 months are used in practice, though formal long-term trials in the adult off-label population are limited.
References
- Human growth hormone and human aging Endocrine Reviews, 1993. PMID: 8491152. https://pubmed.ncbi.nlm.nih.gov/8491152/
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 2006. PMC2682459. https://pmc.ncbi.nlm.nih.gov/articles/PMC2682459/
- The Safety and Efficacy of Growth Hormone Secretagogues Sexual Medicine Reviews, 2018. PMC6235963. https://pmc.ncbi.nlm.nih.gov/articles/PMC6235963/
